Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Centessa Pharmaceuticals plcNASDAQ: CNTA
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $72.22M (cash outflow) rose 26.2% year over year, behind the +29.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 29.4% from the prior quarter. Over 3 fiscal years it compounded at -1.3% a year.
Context
- Free cash flow amounted to 1294.6% of revenue in FY2025.
- Free cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +26.2% toward the trailing-twelve-month pace of +29.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (194.19M) USD
- Year-over-year change
- -36.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (194.19M) | -36.7% |
| FY2024 | 2024-12-31 | (142.09M) | +11.5% |
| FY2023 | 2023-12-31 | (160.51M) | +20.4% |
| FY2022 | 2022-12-31 | (201.68M) | -47.9% |
| FY2021 | 2021-12-31 | (136.33M) | — |
Free Cash Flow vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +29.1% is the 7th highest of 10, against a peer median of +41.0%.
- Over three fiscal years its annual growth of -1.3% compares with a peer median of +37.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.2B CNY | +785.9% | +10.5% | 215.2% |
| LTM Jun 2026 | $499.22M USD | +37.9% | +37.2% | — | |
| LTM Mar 2026 | $487.2M USD | +18.0% | -3.6% | 72.8% | |
| LTM Sep 2026 | $357.11M USD | +41.0% | +40.3% | — | |
| LTM Sep 2026 | $320.88M USD | +70.1% | -9.1% | 23.6% | |
| LTM Jun 2026 | $243.95M USD | +7.7% | +141.9% | — | |
| LTM Mar 2026 | $209.17M USD | +29.1% | -1.3% | — | |
| LTM Jun 2026 | $192.16M USD | +59.3% | +61.9% | — | |
| LTM Sep 2026 | $189.17M USD | +61.5% | +64.4% | 3068.0% | |
| LTM Jun 2026 | $162.52M USD | -28.5% | -25.2% | 36.1% | |
| Peer median (excluding CNTA) | — | +41.0% | +37.2% | 72.8% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (381.85M) | (216.21M) | (151.09M) | (235.76M) | (197.53M) |
| Depreciation & Amortization | 34K | 131K | 810K | 942K | 921K |
| Deferred Income Tax | 0 | (2.86M) | (26.53M) | 2.65M | 2.51M |
| Stock-Based Compensation | 0 | 24.97M | 29.39M | 33.55M | 30.96M |
| Change in Working Capital | (5.38M) | (2.83M) | (18.86M) | 22.1M | (51.24M) |
| Accounts Receivables | (6.72M) | (11.71M) | (12.09M) | (6.6M) | 2.91M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 6.35M | (2.72M) | (4.59M) | 2.96M |
| Other Working Capital | 1.34M | 2.53M | (4.04M) | 33.29M | (57.11M) |
| Other Non-Cash Items | 251.06M | (3.75M) | 5.93M | 34.46M | 20.56M |
| Operating Cash Flow | (136.14M) | (200.55M) | (160.34M) | (142.06M) | (193.82M) |
| Capital Expenditures | (185.98K) | (1.14M) | (169K) | (34K) | (371K) |
| Acquisitions (Net) | 63.43M | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (264.91M) | (140.53M) | (739.76M) |
| Sales of Investments | 0 | 0 | 138.08M | 171.83M | 321.6M |
| Other Investing Activities | 0 | 206K | 0 | 0 | 0 |
| Investing Cash Flow | 63.25M | (931K) | (127M) | 31.27M | (418.53M) |
| Debt Repayment | 73.64M | 0 | 0 | (762K) | 0 |
| Common Stock Issued | 586.44M | 718K | 20.81M | 359.61M | 296.72M |
| Common Stock Repurchased | (12K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (261K) | 310K | 5.91M | (5.19M) |
| Financing Cash Flow | 660.07M | 457K | 21.12M | 364.75M | 291.53M |
| Effect of Forex Changes | 2.9M | (418K) | 615K | 1.23M | (448K) |
| Net Change in Cash | 590.08M | (201.44M) | (265.61M) | 255.19M | (321.27M) |
| Free Cash Flow | (136.33M) | (201.68M) | (160.51M) | (142.09M) | (194.19M) |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.